Our website uses cookies so that we can provide you a better online experience and service;
by continuing, you agree to our use of cookies in line with our Privacy Statement
Open submenu
30 Jun 2011 - 10:00

Danisco probiotics study shows reduced common cold symptoms in physically active, healthy individuals

A recent study completed by Griffith University (Queensland, Australia) and the Australian Institute of Sport (Canberra, Australia) supports the health benefits of the Danisco probiotic strain Bifidobacterium lactis Bl-04™ in healthy, physically active adults. Initial results from the study were presented on June 15, 2011, at the International Scientific Conference on Probiotics and Prebiotics (IPC) in Kosice, Slovakia.

The study demonstrated reductions in the incidence, duration and severity of upper respiratory tract illnesses when the subjects received the probiotic B. lactis Bl-04™. Chest illness severity and medication use were also reduced substantially. Professor Allan Cripps, the lead researcher on the study and Pro-Vice Chancellor at Griffith University, said, “The study provides strong evidence for the clinical efficacy of probiotics in healthy adults and is one of the first studies of its kind to do so.”

Target population

Where previous studies have focused on populations whose immune systems are either in developmental stages or on the decline, such as children and the elderly, this study utilized a healthy, active target population. Research indicates that physically active, healthy individuals have lower levels of common colds and respiratory illnesses than sedentary people or those undertaking prolonged intense exercise.

The trial enrolled 474 volunteers for a period of 150 days and reported reductions in upper respiratory tract illness and chest illness of 30-50 percent. Professor David Pyne from the Australian Institute of Sport said, “The results are impressive when you consider the likely magnitude of clinical benefits to physically active individuals.” According to Australian Institute of Sport Director, Peter Fricker, “These findings, which demonstrate benefit in healthy individuals, hold promise for other groups in the population who may be more susceptible to respiratory infections such as the young and elderly.”

Publication pending

Preliminary findings were presented at IPC. Final analysis of the data is ongoing. Full data and more details will become available following publication of the study.

Dedicated to science

Danisco is an acknowledged pioneer within the probiotic field. The company continues to build science behind probiotic strains with gold standard studies on key immune health endpoints and publishes in leading scientific journals.

Further information

Sarah-Jane Jumppanen, Communications Director, Danisco BioActives
Email: sarah.jane.jumppanen@danisco.com

Sarah Jane Jumppanen
Sarah Jane Jumppanen
Communications Director
+44 1737 227720
Reigate, United Kingdom